» Articles » PMID: 36417084

Platelet-derived Microvesicles (PMVs) in Cancer Progression and Clinical Applications

Overview
Specialty Oncology
Date 2022 Nov 23
PMID 36417084
Authors
Affiliations
Soon will be listed here.
Abstract

Platelet-derived microvesicles (PMVs), the microvesicles with the highest concentration in the bloodstream, play a key role in the regulation of hemostasis, inflammation, and angiogenesis. PMVs have recently been identified as key factors in the link between platelets and cancer. PMVs bind to both cancer cells and nontransformed cells in the microenvironment of the tumor, and then transfer platelet-derived contents to the target cell. These contents have the potential to either stimulate or modulate the target cell's response. PMVs are encased in a lipid bilayer that contains surface proteins and lipids as well as components found inside the PMV. Each of these components participates in known and potential PMV roles in cancer. The complicated roles played by PMVs in the onset, development, and progression of cancer and cancer-related comorbidities are summarized in this study.

Citing Articles

Elevated platelet distribution width and diabetes may serve as preoperative predictors of microvascular invasion in primary hepatocellular carcinoma.

Wang L, Jun L, Jianan J, Chunmei R, Yuhuan J, Peng L J Cancer Res Clin Oncol. 2025; 151(3):111.

PMID: 40085250 DOI: 10.1007/s00432-025-06157-2.


Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment.

Zhuang T, Wang S, Yu X, He X, Guo H, Ou C Biomark Res. 2024; 12(1):88.

PMID: 39183323 PMC: 11346179. DOI: 10.1186/s40364-024-00639-0.


Precision Oncology: Circulating Microvesicles as New Biomarkers in a Very Early Stage of Colorectal Cancer.

Kriebardis A, Chardalias L, Damaskos C, Pouliakis A, Garmpis N, Fortis S Cancers (Basel). 2024; 16(10).

PMID: 38792021 PMC: 11119677. DOI: 10.3390/cancers16101943.


Platelet lipidomics and de novo lipogenesis: impact on health and disease.

Pirotton L, de Cartier dYves E, Bertrand L, Beauloye C, Horman S Curr Opin Hematol. 2024; 31(5):217-223.

PMID: 38727017 PMC: 11296274. DOI: 10.1097/MOH.0000000000000820.


Platelet-derived microparticles and their cargos: The past, present and future.

Guo J, Cui B, Zheng J, Yu C, Zheng X, Yi L Asian J Pharm Sci. 2024; 19(2):100907.

PMID: 38623487 PMC: 11016590. DOI: 10.1016/j.ajps.2024.100907.


References
1.
Gurbel P, Jeong Y, Navarese E, Tantry U . Platelet-Mediated Thrombosis: From Bench to Bedside. Circ Res. 2016; 118(9):1380-91. DOI: 10.1161/CIRCRESAHA.115.307016. View

2.
Zaldivia M, McFadyen J, Lim B, Wang X, Peter K . Platelet-Derived Microvesicles in Cardiovascular Diseases. Front Cardiovasc Med. 2017; 4:74. PMC: 5702324. DOI: 10.3389/fcvm.2017.00074. View

3.
Tafelmeier M, Fischer A, Orso E, Konovalova T, Bottcher A, Liebisch G . Mildly oxidized HDL decrease agonist-induced platelet aggregation and release of pro-coagulant platelet extracellular vesicles. J Steroid Biochem Mol Biol. 2016; 169:176-188. DOI: 10.1016/j.jsbmb.2016.05.003. View

4.
Zmigrodzka M, Witkowska-Pilaszewicz O, Winnicka A . Platelets Extracellular Vesicles as Regulators of Cancer Progression-An Updated Perspective. Int J Mol Sci. 2020; 21(15). PMC: 7432409. DOI: 10.3390/ijms21155195. View

5.
Lazar S, Goldfinger L . Platelet Microparticles and miRNA Transfer in Cancer Progression: Many Targets, Modes of Action, and Effects Across Cancer Stages. Front Cardiovasc Med. 2018; 5:13. PMC: 5850852. DOI: 10.3389/fcvm.2018.00013. View